Price
No data yet.
Social Signal Score
37
5d
37
1 mentions
—
30d
37
1 mentions
—
60d
37
1 mentions
—
90d
37
1 mentions
—
news: 1
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 0.41
- Country
- US
Quote
Day Range
$112.49 – $113.45
52-Week Range
$85.91 – $114.57
Volume
$204.0K
Market Cap
$983.50M
50-Day Avg
$108.96
200-Day Avg
$104.74
Prev Close
$111.08
Open
$112.49
Valuation & Ratios
P/E Ratio
—
EPS
—
P/B Ratio
—
P/S Ratio
—
Debt/Equity
—
Current Ratio
—
Dividend Yield
—
Gross Margin
—
Returns & Efficiency
Return on Equity
—
Return on Assets
—
FCF Yield
—
EV/EBITDA
—
Valuation
PPHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
87Aug 18Aug 18
Social Signal Score
37
5d
37
1 mentions
—
30d
37
1 mentions
—
60d
37
1 mentions
—
90d
37
1 mentions
—
news: 1
Mentions (1)
- Newsfool.com·23h ago·Negative
Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? VanEck Pharmaceutical ETF offers a lower-volatility profile and a higher 1.9% dividend yield compared to State Street SPDR S&P Biotech ETF. State Street SPDR S&P Biotech ETF provides broad exposure with 155 holdings, whereas VanEck Pharmaceutical ETF is concentrated in 26 major drugmakers.
View source ↗